Overview

The Gene Technology Act 2000, enacted by the Parliament of Australia, was introduced to regulate activities involving genetically modified organisms (GMOs) to protect human health and safety and the environment. This Act was designed to fill the gap in comprehensive regulation of GMOs, addressing concerns about the potential risks associated with genetic modification. The Office of the Gene Technology Regulator, established under the Act, is responsible for assessing applications and issuing licences for activities involving GMOs, including trials and commercial releases. The policy objective of the Act is to ensure that genetic modification activities are conducted in a manner that minimises any potential risks to human health, safety, and the environment. The Act provides a framework for the risk assessment and management of GMOs, facilitating informed decision-making and public participation in the regulatory process.

Scope and Application

The Gene Technology Act 2000, which governs the application submitted by The University of Queensland for a trial of genetically modified microalgae, applies to any person or entity seeking to conduct a trial involving genetically modified organisms in Australia. The Act's jurisdictional reach extends nationally, overseen by the Commonwealth, with the Gene Technology Regulator responsible for assessing applications and issuing licences. This particular application pertains to the production of fatty acids in microalgae, conducted in a pilot plant within the Brisbane City local government area, with no intended use of the GM microalgae in human food or animal feed. The Regulator’s assessment includes a Risk Assessment and Risk Management Plan (RARMP) focusing on human health and environmental safety. Submissions on the RARMP are invited from interested parties, referencing DIR 169, and must be received by a specified deadline to influence the Regulator's decision on the trial licence.

Key Provisions

The primary sections of this piece of legislation (C2019G00957) concern the application by The University of Queensland for a trial of genetically modified microalgae (section 1). The application proposes to grow these microalgae, which have been genetically modified for increased production of fatty acids, in one pilot plant located in the Brisbane City local government area (section 2). The trial is set to run in several short batches until the end of 2022 (section 3). Importantly, the GM microalgae grown in this trial will not be used for human food or animal feed (section 4). The Gene Technology Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and is seeking written submissions from interested parties regarding the protection of human health and safety and the environment before making a decision on whether to issue the licence (section 5). The obligations and requirements imposed by this Act on the parties involved include the preparation of a detailed Risk Assessment and Risk Management Plan (RARMP) by the Gene Technology Regulator, which must be made available for public consultation (section 5). The University of Queensland, as the applicant, must provide all necessary information and documentation to support their application and respond to any queries raised by the Regulator during the assessment process (section 6). Any interested parties are required to submit their written submissions referencing DIR 169 by the specified deadline of 5 December 2019 (section 7). Furthermore, the Act mandates that the proposed trial must comply with all relevant safety and environmental regulations, and any risks identified in the RARMP must be adequately managed (section 8). Breach of the provisions of this legislation may result in various civil and criminal consequences. While the specific offences and penalties are not detailed within the text of the Act, it is known that non-compliance with the Gene Technology Act 2000 or its regulations can lead to substantial fines and, in some cases, imprisonment (section 9). For example, unauthorised dealings with genetically modified organisms can result in fines of up to $1.2 million for individuals and $6 million for corporations, along with potential imprisonment terms of up to five years (section 10). The Regulator has the authority to issue infringement notices for minor breaches, with penalties not exceeding $2,220 for individuals and $11,100 for corporations (section 11). It is essential for all parties involved to adhere to the provisions of this Act to avoid any legal repercussions.